Non-invasive imaging of vulnerable plaques by molecular targeting of oxidized LDL with tagged oxidation-specific antibodies

Journal of Cellular Biochemistry

Volumn , Issue SUPPL. 39, 2002, Pages 138-146

  Tsimikas, Sotirios ^a,b   Shaw, Peter X ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Lipoproteins; Oxidation; Plaque rupture; Radioisotopes; Radionuclide imaging

Indexed keywords

ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; AUTOANTIBODY; LOW DENSITY LIPOPROTEIN; RADIOACTIVE IODINE;

ACUTE HEART INFARCTION; ANTIBODY SPECIFICITY; ARTERY OCCLUSION; ARTERY RUPTURE; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; DIAGNOSTIC IMAGING; DISEASE COURSE; ECHOGRAPHY; GENE THERAPY; HUMAN; ISCHEMIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION; PRIORITY JOURNAL; SCINTIGRAPHY; SUDDEN DEATH; ANIMAL; CORONARY ARTERY ATHEROSCLEROSIS; GAMMA RADIATION; HYPERLIPIDEMIA; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY; RABBIT; RADIOIMMUNOASSAY;

ANIMALIA;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CORONARY ARTERIOSCLEROSIS; DIAGNOSTIC IMAGING; GAMMA RAYS; HUMANS; HYPERLIPIDEMIAS; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; LIPOPROTEINS, LDL; MICE; OXIDATION-REDUCTION; RABBITS; RADIOIMMUNODETECTION;

EID: 0036987055     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10420     Document Type: Article

References (36)

1. Aikawa M, Sugiyama S, Hill CC, Voglic SJ, Rabkin E, Fukumoto Y, Schoen FJ, Witztum JL, Libby P. 2002. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 106:1390-1396.
2. Carpenter KL, Taylor SE, van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ. 1995. Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. Biochim Biophys Acta 1256:141-150.
3. Chang MK, Bergmark C, Laurila A, Hörkkö S, Han KH, Friedman P, Dennis EA, Witztum JL. 1999. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: Evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci USA 96:6353-6358.
4. Constantinides P. 1966. Plaque fissures in human coronary thrombosis. J Atheroscler Res 6:1-17.
5. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. 2001. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 103:926-933.
6. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. 1999. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo Edeficient mice. J Clin Invest 103:1597-1604.
7. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. 1993. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 69:377-381.
8. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. 1980. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897-902.
9. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. 2001. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103:1955-1960.
10. Felton CV, Crook D, Davies MJ, Oliver MF. 1997. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 17:1337-1345.
11. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. 1987. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316: 1371-1375.
12. Holvoet P, Collen D, van de Werf F. 1999. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 281:1721.
13. Hulthe J, Bokemark L, Fagerberg B. 2001. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21:101-107.
14. Navab M, Berliner JA, Watson AD, Hama S, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM. 1996. The yin and yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 16:831-842.
15. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S. 2002. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 22:1649-1654.
16. Nissen SE. 2002. Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am J Cardiol 89:24-31.
17. Palinski W, Witztum JL. 2000. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 247:371-380.
18. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. 1990. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10:325-335.
19. Penny WF, Ben Yehuda O, Kuroe K, Long J, Bond A, Bhargava V, Peterson JF, McDaniel M, Juliano J, Witztum JL, Ross J, Jr., Peterson KL. 2001. Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: Heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol 37:766-774.
20. Piotrowski JJ, Shah S, Alexander JJ. 1996. Mature human atherosclerotic plaque contains peroxidized phosphatidylcholine as a major lipid peroxide. Life Sci 58:735-740.
21. Praticó D. 1999. F(2)-isoprostanes: Sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 147:1-10.
22. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL. 1990. Distribution of oxidation specific lipidprotein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 10:336-349.
23. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. 2001. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 285:1711-1718.
24. Shaw PX, Hörkkö S, Tsimikas S, Chang MK, Palinski W, Silverman GJ, Chen PP, Witztum JL. 2001. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 21:1333-1339.
25. Superko HR, Krauss RM. 1994. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 90:1056-1069.
26. Tsimikas S, Witztum JL. 2000. The oxidative modification hypothesis of atherosclerosis. In: Keaney JF, editor. Oxidative stress and vascular disease. Boston: Kluwer Academic Publishers. p 49-74.
27. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. 1999. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 6:41-53.
28. Tsimikas S, Shortal BP, Witztum JL, Palinski W. 2000. In vivo uptake of radiolabeled MDA2, an oxidationspecific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 20:689-697.
29. Tsimikas S, Palinski W, Witztum JL. 2001a. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 21:95-100.
30. Tsimikas S, Witztum JL. 2001b. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 103:1930-1932.
31. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL. 2003. Temporal increases in plasma markers of oxidized LDL strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol.
32. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. 2000. Lessons from sudden coronary death: A comprehensive morphological classification scheme for athero-sclerotic lesions. Arterioscler Thromb Vasc Biol 20: 1262-1275.
33. Williams KJ, Tabas I. 1998. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 9:471-474.
34. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84:1086-1095.
35. Yuan C, Zhang Sx, Polissar NL, Echelard D, Ortiz G, Davis JW, Ellington E, Ferguson MS, Hatsukami TS. 2002. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 105:181-185.
36. Zhao XQ, Yuan C, Hatsukami TS, Frechette EH, Kang XJ, Maravilla KR, Brown BG. 2001. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: A case-control study. Arterioscler Thromb Vasc Biol 21: 1623-1629.